Pressure points in primary care: Blood pressure and management of hypertension in 532 050 patients from 2005 to 2010

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1265-1271

  Carrington, Melinda J ^a   Jennings, Garry L ^a   Stewart, Simon ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

antihypertensive treatment; blood pressure; cardiovascular disease; hypertension; management; primary care; treatment targets

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSTRALIA; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY;

EID: 84877584215     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283606bc7     Document Type: Article

References (24)

1. He FJ, MacGregor GA. Blood pressure is the most important cause of death and disability in the world. Eur Heart J Suppl 2007; 9 (Supp B):B23-B28.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
3. Australian Institute of Health and Welfare. Australia's health 2010. Canberra, ACT, Australia: AIHW cat. no. AUS 122; 2010.
4. Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ, et al. Untreated hypertension among Australian adults: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 2003; 179:135-139.
5. Carrington MJ, Jennings GL, Stewart S. Pattern of blood pressure in Australian adults: results from a national blood pressure screening day of 13,825 adults. Int J Cardiol 2010; 145:461-467.
6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
7. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010:CD005182.
8. Ernst ME. Resistant hypertension or resistant prescribing? Hypertension 2011; 58:987-988.
9. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Canberra, ACT: National Heart Foundation of Australia; 2008.
10. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895-905.
11. Health Communication Network. http://www.hcn.com.au/. (Accessed 14 October 2011).
12. O'Brien E, Petrie J, Littler W, de Swiet M, Padfield PL, Altman DG, et al. An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens 1993; 11:677-679.
13. Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) 2012; 14:744-750.
14. Department of Health and Ageing. PBS expenditure and prescriptions twelve months to 30 June 2010. Canberra, ACT: Department of Health and Aging; 2010.
15. Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48:385-391.
16. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlof B, Velazquez EJ, et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17:7-17.
17. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
18. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting: enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
19. Stewart S, Carrington MJ, Swemmer C, Kurstjens N, Jennings GL. Optimising management of hypertension in primary care: The Valsartan Intensified Primary Care Reduction of Blood Pressure (Viper-Bp) Study. Int J Cardiol 2011; 153:317-322.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
21. Stewart S, Carrington MJ, Swemmer CH, Kurstjens NP, Anderson C, Amerena J, et al. A pragmatic, multicentre, randomised controlled trial of a guideline based, computer-assisted, structured care algorithm in achieving individual blood pressure targets in primary care. BMJ 2012; 345:e7156.
22. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124-1131.
23. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53:646-653.
24. Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011; 8:686-693.